Repare Therapeutics Past Earnings Performance
Past criteria checks 0/6
Repare Therapeutics's earnings have been declining at an average annual rate of -5.9%, while the Biotechs industry saw earnings growing at 15% annually. Revenues have been growing at an average rate of 69.7% per year.
Key information
-5.9%
Earnings growth rate
72.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 69.7% |
Return on equity | -19.7% |
Net Margin | -46.7% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues
May 01Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet
Mar 12We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully
Feb 15Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth
Dec 20Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
Oct 24New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)
Aug 14Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week
May 14Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results
May 12Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough
May 08Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%
Mar 03Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Oct 27Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners
Sep 07Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M
Aug 04Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go
Jun 27Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Jun 24Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans
Mar 02We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn
Oct 14We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Apr 16Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?
Mar 12Are Institutions Heavily Invested In Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares?
Feb 08Repare Therapeutics: CRISPR-Enabled Technology Might Unlock New Therapies
Dec 28Trade Alert: The Executive VP & Head of Business & Corporate Development Of Repare Therapeutics Inc. (NASDAQ:RPTX), Kim Seth, Has Sold Some Shares Recently
Dec 21We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Nov 19Revenue & Expenses Breakdown
How Repare Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 98 | -46 | 36 | 1 |
31 Dec 23 | 51 | -94 | 36 | 0 |
30 Sep 23 | 56 | -97 | 35 | 7 |
30 Jun 23 | 167 | -3 | 35 | 6 |
31 Mar 23 | 137 | -29 | 35 | 0 |
31 Dec 22 | 132 | -29 | 35 | 0 |
30 Sep 22 | 121 | -26 | 34 | 82 |
30 Jun 22 | 8 | -132 | 33 | 53 |
31 Mar 22 | 8 | -120 | 32 | 0 |
31 Dec 21 | 8 | -107 | 28 | 0 |
30 Sep 21 | 1 | -94 | 25 | 0 |
30 Jun 21 | 1 | -77 | 22 | 0 |
31 Mar 21 | 0 | -62 | 19 | 0 |
31 Dec 20 | 0 | -53 | 16 | 0 |
30 Sep 20 | 0 | -46 | 12 | -14 |
30 Jun 20 | 0 | -40 | 10 | -9 |
31 Mar 20 | 0 | -35 | 7 | -4 |
31 Dec 19 | 0 | -27 | 6 | 0 |
31 Dec 18 | 0 | -14 | 3 | 10 |
Quality Earnings: RPTX is currently unprofitable.
Growing Profit Margin: RPTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RPTX is unprofitable, and losses have increased over the past 5 years at a rate of 5.9% per year.
Accelerating Growth: Unable to compare RPTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RPTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: RPTX has a negative Return on Equity (-19.7%), as it is currently unprofitable.